Please assess the completion status of the following clinical trial:

Trial Title: A Mobile Application to Promote Self-management and Improve Outcomes in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older at screening~2. Currently admitted or discharged from the hospital within the last 14 days with a diagnosis of acute or acute on chronic decompensated HF.~3. Based on one of the EF criteria (LVEF within 12 months of randomization. BNP or NT-proBNP criteria within 30 days prior to randomization):~   * Left ventricular ejection fraction (LVEF) ≤ 40%.~  * LVEF \>40% and BNP \> 175 pg/ml or NT-proBNP \> 700 pg/ml. Thresholds for NT-proBNP and BNP for LVEF \> 40% will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2.~4. Have a personal physician for follow-up~5. A smartphone with a compatible Apple or Android operating system installed and able to download and use ManageHF including accepting all permissions~6. A valid email address~7. Fluent in spoken and written English~Exclusion Criteria:~1. Contraindication to recommending a sodium restriction diet~2. Scheduled intervention for primary valvular heart disease will occur during the study period.~3. Cardiac resynchronization therapy (CRT) within 3 months prior to screening or current plan to implant CRT device during the study period.~4. Dialysis~5. Previous cardiac transplantation or implantation of a ventricular assistance device or similar device.~6. Listed status 1, 2 or 3 for heart transplant~7. Implantation of a ventricular assistance device is expected within 3 months after randomization~8. Non-cardiac illness with expected survival of less than 3 months~9. Discharge to a setting other than home~10. Requirement for chronic inotropic therapy (e.g. milrinone, dobutamine)~11. Inability to use Withings devices due to equipment limitations or contraindications~12. Currently pregnant or intend to become pregnant during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group 'A' (Type: SHAM_COMPARATOR): Standard heart failure educational information.
- Dietary Sodium Intervention 'B' (Type: EXPERIMENTAL): The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
- Clinical Worsening Intervention 'C' (Type: EXPERIMENTAL): The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
- Dietary Sodium and Clinical Worsening 'D' (Type: EXPERIMENTAL): Full access to all content in the control, dietary sodium, and clinical worsening interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).